MicroRNA155 Expression in Relation to BDCAF Scored Behçet's Disease in an Egyptian Patients' Sample

Sally S Hassouna; Manal Y Tayel; Dalal M ElKaffash; Ahmed M Abdelhady; Eman H Elsayed

doi:10.2174/1874312901812010115

MicroRNA155 Expression in Relation to BDCAF Scored Behçet's Disease in an Egyptian Patients' Sample

Open Rheumatol J. 2018 Jul 31:12:115-122. doi: 10.2174/1874312901812010115. eCollection 2018.

Authors

Sally S Hassouna¹, Manal Y Tayel¹, Dalal M ElKaffash², Ahmed M Abdelhady³, Eman H Elsayed¹

Affiliations

¹ Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
² Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
³ Department of Opthalmology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.

Abstract

Objective: To discover the possibility of using microRNA155 (miRNA155) expression level as a biomarker of Behçet's Disease (BD) activity or remission.

Methods: Thirty BD patients' white blood cells (WBCs) miRNA155 expression was measured and compared to WBCs miRNA155 expression in 15 healthy subjects. Assessment of disease activity was done using Behçet's Disease Current Activity Form (BDCAF).

Results: miRNA155 expression significantly decreases with the increase of BD activity scored by BDCAF.

Conclusion: Increased miRNA155 may be used as a biomarker of BD remission and thus in the disease follow up. There could be a prospect of treating the disease via microRNA 155 effect enhancement.

Keywords: BDCAF; Behçet's disease; CD40; Egyptian patients; MicroRNA155; miRNA155.